CNS Response, Inc. Names Henry T. Harbin, MD to Board of...(country. Dr.Harbin held several executiv...),Health

Among his achievements in research, Dr. Harbin was a principal investigator and project director for multiple studies at the University of Maryland's Institute of Psychiatry and Human Behavior, and has served as a reviewer for the American Journal of Psychiatry, Journal of Nervous and Mental Disease, and Hospital & Community Psychiatry. Dr. Harbin has also been published in over 10 peer-reviewed articles.

Dave Jones, Managing Partner of Sail Venture Capital and a member of the CNS Response Board of Directors, remarked, "The experience and enthusiasm of the people becoming associated with CNS Response, including Dr. Henry Harbin, our new President, George Carpenter, the new Chief Medical Officer, Daniel Hoffman, MD, and others joining Len, combined with the core team, allows this company to capitalize on its extraordinary vision and opportunity."

About CNS Response

CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(SM) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment
'/>"/>